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Edited by Robert RussellAbstract The dominant conceptual reductionism in drug discov-
ery has resulted in many promising drug candidates to fail during
the last clinical phases, mainly due to a lack of knowledge about
the patho-physiological pathways they are acting on. Conse-
quently, to increase the revenues of the drug discovery process,
we need to improve our understanding of the molecular mecha-
nisms underlying complex cellular processes and consider each
potential drug target in its full biological context. Here, we re-
view several strategies that combine computational and experi-
mental techniques, and suggest a systems pathology approach
that will ultimately lead to a better comprehension of the molec-
ular bases of disease.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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In the past century, biomedical sciences have been clearly
immersed in a conceptual reductionism induced by the success
of molecular biology. The development of methods to isolate
and study individual cells and molecules has signiﬁcantly in-
creased our understanding of the nature of life and has led
to important societal advances, including the development of
new medicines. The last years have seen the climax of these ap-
proaches with the many genome sequencing projects providing
nearly complete lists of the macromolecules present in an
organism, including humans [1]. However, biological systems
are often complex in nature, and the knowledge of the compo-
nents reveals relatively little about their function and organisa-
tion. The scientiﬁc community is now aware of the diﬃculties
of predicting the behaviour of an intact organism from the
individual actions of its parts in isolation and is rapidly mov-
ing to systems approaches, where also global properties are
considered. Actually, most follow-up initiatives to the sequenc-
ing projects have been directed towards solving the systems
complexity, and have focused on unveiling the millions of
interrelationships between macromolecules in an organism or*Corresponding authors. Fax: +34 932158016 (J.M. Mas), +34
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doi:10.1016/j.febslet.2008.02.014on monitoring how they coordinately change in response to
a particular stimulus such as the onset of a disease. Indeed,
functional genomics initiatives are already delivering the ﬁrst
drafts of whole organism interactomes [2–4], gene expression
proﬁles for many diﬀerent tissues and conditions [5,6], as well
as the initial quantiﬁcations of metabolites in human [7,8].
Pharmacological sciences have gone through an analogous
course, with traditional approaches being mostly reduced to
the study, at molecular level, of the target-compound duet.
However, the truth is that phenotypic observations (i.e. disease
symptoms) are often the result of an incredibly complex com-
bination of molecular events [9]. This is because virtually every
major biological process is not carried out by a single molecule
but by large macromolecular assemblies and is often regulated
through a complex network of transient interactions. More-
over, since most pathways are interconnected, slight changes
in these transient regulatory networks can trigger a variety of
processes, with remarkably diﬀerent results.
This reductionism has had striking consequences. For
instance, many promising drug candidates have failed the last,
and most expensive, clinical phases because the action mecha-
nisms of the pathways they target are still poorly understood
or due to an inappropriate choice of animal models that
proved ineﬀective at predicting oﬀ-target eﬀects [10]. It is thus
clear that, to increase the revenues of drug discovery, we need
to improve our knowledge of the molecular mechanisms of dis-
ease, consider the full biological context of a drug target and
move beyond individual genes and proteins.
Ideally, the global molecular characterization of pathologi-
cal pathways requires a combination of computational biology
approaches and interaction discovery techniques. This should
ultimately culminate in a real dry-wet cycle, where computa-
tional modelling is used to design the experiments needed to
complement and complete the initial pathways, and where
the experimental results are employed to further reﬁne the
computational models. Indeed, we would suggest to start with
the in silico modelling, since it brings the additional advantage
of not being restricted to the study of only one or a few patho-
physiological pathways. On the contrary, it allows to globally
model all human biological routes that might arise from exist-
ing data, which will reveal novel and unexpected connections
between known pathways. Afterwards it is still possible to
focus on those pathways that look more interesting from a
clinical perspective [11,12].
A deeper understanding of the molecular mechanisms be-
neath a disease phenotype will ﬁnally permit the discovery of
new potential drug targets, suggest more eﬀective combinationsblished by Elsevier B.V. All rights reserved.
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model organisms to study a pathological pathway, or identify
disease-speciﬁc biomarkers.2. The rising threshold of innovation
Advances in knowledge and technology have greatly in-
creased our expectations of improved healthcare. The invest-
ment into Research and Development (R&D) of new
medicines has seen spectacular growth over the past decade,
but despite technical progress in drug discovery technologies,
there has not been a concomitant increase in R&D productiv-
ity [13]. The current developments in the basic discovery sci-
ences have not been mirrored by simultaneous progress in
understanding the molecular bases of disease. Therefore, the
development of novel eﬀective therapies [14,15] and, as a con-
sequence, the number of new drug applications submitted to
the Food and Drug Administration (FDA) has decreased dur-
ing the past 10 years [16]. For example, data on product attri-
tion rates [17,18] indicate that the probability of a drug
candidate passing from pre-clinical stages (i.e. the ﬁrst Good
Laboratory Practice (GLP) toxicity study) to market is 6%
or less. The most common factors resulting in project failure
have been reported as either a lack of eﬃcacy (25%), clinical
safety concerns (12%) or toxicological ﬁndings in pre-clinical
evaluation (20%). Reducing the risks associated with project
failure is dependent upon a concerted and collaborative eﬀort
to address these bottlenecks in the drug development process.
Indeed, one of the biopharmaceutical industrys greatest needs
is for failure to be predicted at the earliest possible stage of the
drug development pipeline.
Another clear indicator is the fact that, since 1960, the gap
between the number of approved drugs and that of diseases
for which at least one treatment is available has constantly in-
creased (Fig. 1). This somehow indicates that even the most0
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Fig. 1. Temporal development of the total number of approved drugs
and treated diseases. Comparison of the total number of approved
drugs (blue triangles) and the total number of treated diseases (orange
circles) since the end of World War II. The graph contains only those
drugs from DrugBank [77] which have been approved by the FDA and
target known genetic diseases or complex traits stored in OMIM [78].
These datasets are, of course, far from comprehensive, however, we
believe that the observed trends can be extrapolated to all marketed
drugs and known diseases.successful stories in pharmacological R&D often end with a
compound put in the market that is only a variation on a
known drug, rather than a completely new chemical entity di-
rected to the treatment of a novel disease.
A number of authors have raised the concern that the
current drug discovery process, based on in vitro screening
techniques and animal models of often poorly understood clin-
ical relevance, is fundamentally unable to identify candidates
with a high probability of eﬀectiveness [19,20]. The current sci-
entiﬁc understanding of both physiology and patho-physiolog-
ical processes is of necessity reductionistic, and thus does not
constitute knowledge at the systems level of a cell, organ, or
whole organism.
We believe that a systems biology approach (Fig. 2) can oﬀer
a new view on how biopharmaceutical research can be tackled
in the discovery of new therapeutic targets and disease bio-
markers, the improvement of predicting the safety and eﬃcacy
evaluation of new potential drugs, and the disclosure of new
indications for existing drug candidates.3. Seed interactome
The ﬁrst step when trying to model a signalling or metabolic
pathway in a global fashion is to build an initial interactome
based on a given set of seed proteins. If we are interested in
a certain disease, we could well start by identifying those pro-
teins that have been found to be involved in the respective
pathological process by genetical or physical mapping of hu-
man disease loci, positional cloning of disease genes [21] or
genome-wide association studies [22].
For some diseases, the patho-physiological pathways have
already been extensively studied, which opens up the possibil-
ity to build the seed interactome from all the proteins docu-
mented to be involved in the given signalling or metabolic
route. There are currently some excellent databases, hand-cu-
rated by experts, where all this information is stored (e.g.
Reactome [23] and KEGG [24]).
Instead of using disease-related proteins or pathways as
seeds, it is also possible to start from a drug-centered point
of view by using the drug-target relationships to identify target
proteins of drugs developed for the given disease and to build
the seed interactome around those proteins. This allows to
study the biological context of drug targets in order to be bet-
ter able to predict the physiological consequences of drug
application, including potential adverse eﬀects [25]. For in-
stance, there are certain marketed drugs, like Ziprasidone
and Olanzapine (prescribed for treating Schizophrenia and
Bipolar disorder), for which more than 10 targets are known,
representing a pretty comprehensive set of seed proteins.
After having collected a set of seed proteins, the seed inter-
actome can then be created by putting those proteins in the
context of known binary protein–protein interactions and
complex memberships extracted from public databases such
as IntAct [26], MINT [27], HPRD [28] and CORUM [29]. It
is also possible to further include protein interactions derived
from neighboring steps in enzymatic reactions extracted from
KEGG or those resulting in post-translational modiﬁcations
from databases like Phospho.ELM [30] and HPRD.
Two recent articles have just implemented the strategy sug-
gested above to build seed interactomes from disease-related
proteins. Limviphuvadh et al. built the interaction networks
Fig. 2. Global strategy for the molecular characterisation of pathways
and potential clinical applications. Starting from a set of seed proteins,
an initial interactome is built using known protein–protein interac-
tions. The resulting seed interactome or pathway is then extended and
validated before putting the pathway components into a spatio-
temporal context based on gene expression data. Perturbation of the
system ﬁnally allows to unveil relationships between pathway topology
and biological activity, with important implications for several kinds of
clinical applications (see main text for details).
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mers disease, Parkinsons disease, Amyotrophic lateral sclero-sis, Huntingtons disease, Dentatorubropallidoluysian atrophy,
and Prion disease) [31], and Pujana et al. created a breast cancer
interactome starting from four known breast cancer associated
genes (i.e. BRCA1, BRCA2, ATM and CHK2) [32]. On the
other hand, Lu et al. outlined the advantages of embedding
known biological pathways into protein–protein interaction
networks [33]. First, it can reveal new interactions between al-
ready known pathway members, and second, it allows to iden-
tify new proteins involved in a given pathway as well as
overlapping or linking components among pathways.4. Pathway extension and validation
Our knowledge of the human interactome is still far from
complete, although three recent large-scale studies already be-
gan to systematically map all human protein–protein interac-
tions [2–4]. This implies that also the seed interactome
created using known physical interactions is fragmentary and
only contains a part of all relevant interactions. Thus, it is nec-
essary, as the next step, to expand the seed interactome.
One possibility to do so, is by including interactions discov-
ered in other species through orthology relationships. This is
especially interesting because, compared to human, in total
there have many more interactions been described in diﬀerent
model organisms such as yeast [34–37], worm [38] and ﬂy [39].
Matthews et al. were the ﬁrst to assess whether a protein inter-
action network generated in one species can be used to predict
interactions in other organisms [40]. They performed system-
atic BLAST [41] searches for pairs of potential orthologs of
known interacting partners in yeast, in order to identify poten-
tially conserved interactions in worm, named interologs. In-
deed, similar approaches were used more recently to increase
the number of potential protein–protein interactions in human
[42,43]. In addition to such orthology relationship-based meth-
ods, several other protein–protein interaction prediction ap-
proaches were developed in the last years, for which
comprehensive reviews are provided in Refs. [44,45]. Indepen-
dent of the particular method used, when extrapolating inter-
actions from one organism to the other, it is important to
realise that, very often, there is no direct equivalence, and a
single protein in a model organism like yeast might have
evolved into a whole protein family in human. Thus, it is piv-
otal to consider how the speciﬁcity is achieved in interactions,
a goal towards which, in recent years, remarkable results have
been obtained [46,47].
Another possibility for expanding the seed interactome, is
experimentally by scouting for new interactions. This is, to
use a set of key proteins as probes (baits) and systematically
seek for new potential interactions in cell lysates or large geno-
mic libraries. The main scouting interaction discovery tech-
niques, which have already been successfully applied, are
tandem aﬃnity puriﬁcation coupled to mass spectrometry
(TAP-MS) and the yeast two-hybrid (Y2H) system [48]. For
instance, Bouwmeester et al. used TAP-MS to map the human
protein interaction network around 32 known TNF-a/NF-jB
pathway components, and identiﬁed 221 molecular associa-
tions and 80 previously unknown interactors, providing new
insights into this inﬂammation-related signalling route [49].
Alternatively, Lim et al. employed the Y2H technique to fur-
ther characterise the protein interaction network involved in
Purkinje cell degeneration, characteristic of several human
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interactions [50]. There also exist a couple of derived methods
like the split-ubiquitin Y2H system [51] and the G-protein fu-
sion technique [52], speciﬁcally designed for the detection of
interactions involving membrane proteins, and the tethered
catalysis two-hybrid assay which enables the discovery of pro-
tein–protein interactions that require a speciﬁc posttransla-
tional modiﬁcation [53].
A combined approach was pursued by Pujana et al. who
used both computational inference of protein interactions via
orthology and experimental Y2H screens in a network model-
ling strategy to identify genes associated with higher risk of
breast cancer, uncovering a genetic link between breast cancer
susceptibility and centrosome dysfunction [32].
The diﬀerent interaction detection methods which can be
used for pathway extension have in common that none of them
is comprehensive, meaning that they report many false interac-
tions and are bound to miss some real ones [54]. This is espe-
cially problematic in the case of scouting techniques which, in
exchange for being applicable in high-throughput studies, ac-
cept risky procedures such as rough washes, experimentation
under non-physiological conditions and gene overexpression,
that lead to an increase in false positive and false negative
interactions. Consequently, recent publications try to address
this issue by assigning a probability or conﬁdence value to
every interaction in the network, usually based on a so-called
gold standard set of high-conﬁdence interactions [55,56]. Nev-
ertheless, the uncertainty of reported interactions implies a
high likeliness that even the extended interactome or pathway
is yet incomplete and contains some incorrect interactions. It is
therefore crucial to validate those interactions which are either
unexpected or key for interpreting the constructed protein
interaction map. This validation can be accomplished by the
use of ﬁner techniques which feature very low false positive
and false negative rates, and are thus suited for conﬁrming
interactions, such as ﬂuorescence resonance energy transfer
(FRET) [57] and the newly developed visual immunoprecipita-
tion (VIP) method [58].5. Pathway comparison and model organism selection
Many clinical studies have failed because the underlying cell
or animal models were poor predictors for human disease [9].
Expanding our knowledge about patho-physiological path-
ways in diﬀerent species forms the basis for developing meth-
ods which will help select the best-suited model organism to
study a given pathology [25]. The main idea here is to compare
the respective human pathway to known interaction networks
and pathways of model species, and assess the pathway simi-
larity [59], in the same way as we can now compare two protein
or DNA sequences.
In the last years, several pathway alignment algorithms have
been developed (e.g. PathBLAST [60], NetworkBLAST [61],
MAWISH [62] and Graemlin [63]), however, the ﬁeld of com-
parative interactomics is still in an early stage [64,65]. Existing
programs suﬀer from certain limitations, such as a ﬁxed assign-
ment of orthologs or no support for intra-species comparison,
which prohibits the detection of alternative pathways, and pre-
vents the identiﬁcationof backup circuits and cross-talk between
pathways of the same species. Furthermore, some programs are
basedonly on an empirical scoring schemeandnot backed-upbyaprobabilisticmodel, or they are tailored towards detecting con-
served complexes and less eﬀective at identifying pathways of
arbitrary topology. Besides, the oﬄine versions of the respective
algorithm implementations are often not very user-friendly.
Thus, there is still room for considerable improvement of
pathway alignment strategies. We argue that, in order to be
widely applicable, a pathway comparison algorithm should
feature fast query-to-network and network-to-network align-
ment (i.e. for ﬁnding pathways in the target network which
are similar to the query, and for discovering conserved com-
plexes or network modules, respectively [65]), as well as both
inter- and intra-species alignment of networks of arbitrary
topology, and support one-to-many and many-to-many
orthology relationships. Another important issue is to analyt-
ically assess the statistical signiﬁcance of the matching path-
ways found, similar to the BLAST E-value [41], which is still
an open problem.
Similar to comparative genomics, which resulted in a deeper
understanding of genome function, organisation and evolu-
tion, we expect comparative interactomics to vastly increase
our knowledge of cellular events, their evolution and adapta-
tion to changing environmental conditions [64]. Good pathway
alignment algorithms will ultimately have very important
implications in many ﬁelds of biology, because they will per-
mit, for instance, to draw phylogenetic trees based on the evo-
lution of complete cellular processes, rather than of their
individual components, and thus to study how certain meta-
bolic or signalling pathways have emerged.6. Time and space
The majority of the data used for seed interactome construc-
tion and pathway extension comes from experiments per-
formed under artiﬁcial conditions, and so only gives concise
information as to whether two proteins can biophysically inter-
act. However, this does not necessarily mean that these two
proteins will interact in vivo. Thus, it is key to distinguish
those interactions that are biophysically possible but will never
happen in the cell from the physiological ones. This means, to
exclude from the extended pathways the interactions involving
proteins that are expressed in diﬀerent sub-cellular localisa-
tions or tissues. For instance, using the information available
in gene expression compendia of normal human tissues
[66,67], it is possible to discriminate those genes that are ubiq-
uitously expressed from those that are speciﬁc to only one or a
few tissues or cell-types. Nonetheless, even if the two proteins,
which have been reported to interact, occur in the same tissue,
it could be that they are expressed in diﬀerent lapses of time,
such as in distinct cell cycle phases or states of disease progres-
sion [68].
Alternatively, instead of ﬁltering out single interactions
occurring between proteins that do not fulﬁl the time and
space constraints, it is possible to ﬁlter out whole pathways
or sub-networks based on their global expression properties.
For example, several methods have been developed which al-
low to assess whether certain pathways or network modules
are coordinately dysregulated in a given disease, and thus pro-
vide a more global view on pathological processes and their
function [69–71]. Those methods can also be used to investi-
gate cross-talk between pathways in diﬀerent conditions and
correlate it to the observed phenotype.
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result will be a detailed interaction map speciﬁc for a given
pathology that can be very valuable, for instance, to suggest
new potential points of intervention (i.e. drug targets). These
candidate targets may be selected based on their pathway
exclusivity, to avoid undesired eﬀects in other routes [25], or
on the topology of the interactome, opting those strategic
enclaves that are vital to steer the network traﬃc in one direc-
tion or another. This would constitute a signiﬁcant advance,
since even the most speciﬁc drugs on the market are directed
towards a target that is not central in the patho-physiological
pathway of the given disease, and are thus producing improve-
ments only in a limited number of symptoms [10].7. Metabolites and small molecules
Following the molecular hierarchy of Nature, the next step
in order to fully characterise a patho-physiological pathway,
is to include the ﬁnal eﬀectors, namely the small molecules
or metabolites present in the human body. The metabolome
is further down the line from gene to function and so reﬂects
more closely the cellular processes at functional level. As a
downstream eﬀect, changes in the metabolome, resulting from
small variations in the quantities of individual enzymes that
only weakly aﬀect global metabolic ﬂuxes, are much more
ampliﬁed than those at transcriptome or proteome level [72].
It has not been until very recently that large-scale metabolo-
mics initiatives started delivering data in a systematic way,
which has prevented, so far, its integration with other high-
throughput genomics or proteomics experiments. However,
2007 has seen the release of the ﬁrst draft of the human metab-
olome [7,8], which includes partial data on metabolite concen-
trations in diﬀerent body tissues and ﬂuids, under a variety of
physiological and pathological conditions. It is, of course,
far from complete but, although it would be ideal to have
information on the status of the whole metabolic complement
of a cell, having data on a small portion of the total metabo-
lome will suﬃce in some instances, such as in selectively mon-
itoring only those metabolites that contribute to a certain
pathway directly associated with a given disease.
The successful integration of metabolomics data into the
molecular descriptions of pathological pathways will represent
a unique opportunity to rationally search for early biomarkers
in body ﬂuids (i.e. blood or urine) and reduce the use of more
invasive techniques, such as tissue biopsies. Also on a clinical
front, it will permit the substitution of phenotypical indica-
tions with disease-speciﬁc biomarkers, and the characterisation
of potential drug-induced toxic eﬀects [73]. As a result, there
will be a substantial reduction of the costs of clinical trials
for drugs against those pathologies that usually require years
of study to reach a clear indication about the usefulness of a
given compound.8. Systems perturbation
Finally, after having assembled a model as complete as pos-
sible of a given patho-physiological pathway, it is important to
assess its validity via perturbations of the system [74]. This can
be achieved, for example, by loss-of-function screens for those
proteins which are part of critical enclaves within a pathwaythrough RNA interference (RNAi) experiments [75], or by
blocking protein activity with speciﬁc inhibitors, followed by
checking whether the obtained response (e.g. redirection of
the metabolic ﬂux, use of alternative signalling routes or cell
death) was correctly predicted by the model. It is thus possible
to relate the structure of a pathway to biological activity,
which has important implications for the discovery of drugs
that exploit topological pathway properties.
To generate a comprehensive molecular description of a gi-
ven pathology, including the systems responses to drug appli-
cation, several diﬀerent states of the system need to be
compared (e.g. diseased vs. healthy or drug-perturbed vs.
-unperturbed), for instance by deriving the so-called system re-
sponse proﬁles (SRPs) [10]. Correlating SRPs caused by path-
way perturbation (e.g. via RNAi) with those induced by drug
candidates allows to determine dynamic system responses to
drug treatment, monitor the progression of a disease or spot
oﬀ-target eﬀects. An elegant implementation of the above ideas
was presented by Workman et al. [76]. The authors applied a
systems approach to construct a global model of yeast tran-
scriptional networks activated by the DNA-damaging agent
methyl-methansulfonate (MMS), and compared the MMS-in-
duced interactions to those reported under normal growth con-
ditions to ﬁnd out how the network was rewired. Gene
expression proﬁling of viable knockout strains permitted the
authors to pinpoint the particular routes involved in transmis-
sion of the DNA damage response signal. The ﬁnal pathway
model explained the expression response of 82 genes upon
MMS-induced DNA damage and identiﬁed cross-talk among
several processes, such as DNA replication and repair, cell
cycle arrest and metabolism [76].9. Concluding remarks
The prevailing reductionism in drug discovery resulted in
many promising drug candidates to fail in the last clinical
phases, mainly due to a lack of knowledge about pathological
pathways at the molecular level, which often led to unforeseen
adverse eﬀects. We thus propose a systems pathology ap-
proach, based on both computational modelling and experi-
ments, for achieving a better comprehension of the molecular
bases of human disease. This will ultimately be of substantial
signiﬁcance for the discovery of new drug targets and biomark-
ers, optimisation of preclinical models and understanding of
how biological networks change from health to disease.
Acknowledgements: We would like to acknowledge the ﬁnancial sup-
port received from the Spanish Ministerio de Educacio´n y Ciencia
through the Grants PSE-010000-2007-1 and BIO2007-62426. AZ is a
Juan de la Cierva fellowship recipient.References
[1] Lander, E.S. et al. (2001) Initial sequencing and analysis of the
human genome. Nature 409, 860–921.
[2] Rual, J.-F. et al. (2005) Towards a proteome-scale map of the
human protein–protein interaction network. Nature 437, 1173–
1178.
[3] Stelzl, U. et al. (2005) A human protein–protein interaction
network: a resource for annotating the proteome.Cell 122, 957–968.
[4] Ewing, R.M. et al. (2007) Large-scale mapping of human
protein–protein interactions by mass spectrometry. Mol. Syst.
Biol. 3, 89.
1264 R.A. Pache et al. / FEBS Letters 582 (2008) 1259–1265[5] Barrett, T. et al. (2007) NCBI GEO: mining tens of millions of
expression proﬁles – database and tools update. Nucleic Acids
Res. 35, D760–D765.
[6] Parkinson, H. et al. (2007) ArrayExpress – a public database of
microarray experiments and gene expression proﬁles. Nucleic
Acids Res. 35, D747–D750.
[7] Pearson, H. (2007) Meet the human metabolome. Nature 446, 8.
[8] Wishart, D.S. et al. (2007) HMDB: the human metabolome
database. Nucleic Acids Res. 35, D521–D526.
[9] Lindsay, M.A. (2005) Finding new drug targets in the 21st
century. Drug Discov. Today 10, 1683–1687.
[10] van der Greef, J. and McBurney, R.N. (2005) Innovation:
rescuing drug discovery: in vivo systems pathology and systems
pharmacology. Nat. Rev. Drug Discov. 4, 961–967.
[11] Siegel, P.M. and Massague, J. (2003) Cytostatic and apoptotic
actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer
3, 807–821.
[12] Saltiel, A.R. (2001) New perspectives into the molecular patho-
genesis and treatment of type 2 diabetes. Cell 104, 517–529.
[13] Schmid, E.F. and Smith, D.A. (2006) R&D technology invest-
ments: misguided and expensive or a better way to discover
medicines? Drug Discov. Today 11, 775–784.
[14] Mervis, J. (2005) The hunt for a new drug: ﬁve views from the
inside. Science 309, 722.
[15] Wood, A.J. (2006) A proposal for radical changes in the drug-
approval process. N. Engl. J. Med. 355, 618–623.
[16] Challenge and opportunity on the critical path to new medical
reports. Food and Drug Administration, Rockville, MD (2004).
[17] Global R&D performance metrics programme: industry success
rates report, pp. 7. CMR International (2005).
[18] Kola, I. and Landis, J. (2004) Can the pharmaceutical industry
reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–715.
[19] Duyk, G. (2003) Attrition and translation. Science 302, 603–605.
[20] Horrobin, D.F. (2003) Modern biomedical research: an internally
self-consistent universe with little contact with medical reality?
Nat. Rev. Drug Discov. 2, 151–154.
[21] Broeckel, U. and Schork, N.J. (2004) Identifying genes and
genetic variation underlying human diseases and complex pheno-
types via recombination mapping. J. Physiol. 554, 40–45.
[22] Hirschhorn, J.N. and Daly, M.J. (2005) Genome-wide association
studies for common diseases and complex traits. Nat. Rev. Genet.
6, 95–108.
[23] Vastrik, I. et al. (2007) Reactome: a knowledge base of biologic
pathways and processes. Genome Biol. 8, R39.
[24] Kanehisa, M. et al. (2006) From genomics to chemical genomics:
new developments in KEGG. Nucleic Acids Res. 34, D354–D357.
[25] Apic, G., Ignjatovic, T., Boyer, S. and Russell, R.B. (2005)
Illuminating drug discovery with biological pathways. FEBS Lett.
579, 1872–1877.
[26] Kerrien, S. et al. (2007) IntAct – open source resource for
molecular interaction data. Nucleic Acids Res. 35, D561–D565.
[27] Chatr-aryamontri, A., Ceol, A., Palazzi, L.M., Nardelli, G.,
Schneider, M.V., Castagnoli, L. and Cesareni, G. (2007) MINT:
the Molecular INTeraction database. Nucleic Acids Res. 35,
D572–D574.
[28] Mishra, G.R. et al. (2006) Human protein reference database –
2006 update. Nucleic Acids Res. 34, D411–D414.
[29] Ruepp, A. et al. (2008) CORUM: the comprehensive resource of
mammalian protein complexes. Nucleic Acids Res. 36, D646–
D650.
[30] Diella, F. et al. (2004) Phospho.ELM: a database of experimen-
tally veriﬁed phosphorylation sites in eukaryotic proteins. BMC
Bioinformat. 5, 79.
[31] Limviphuvadh, V., Tanaka, S., Goto, S., Ueda, K. and Kanehisa,
M. (2007) The commonality of protein interaction networks
determined in neurodegenerative disorders (NDDs). Bioinformat-
ics 23, 2129–2138.
[32] Pujana, M.A. et al. (2007) Network modeling links breast cancer
susceptibility and centrosome dysfunction. Nat. Genet. 39, 1338–
1349.
[33] Lu, L.J. et al. (2007) Comparing classical pathways and modern
networks: towards the development of an edge ontology. Trends
Biochem. Sci. 32, 320–331.
[34] Gavin, A.-C. et al. (2006) Proteome survey reveals modularity of
the yeast cell machinery. Nature 440, 631–636.[35] Ito, T., Chiba, T., Ozawa, R., Yoshida, M., Hattori, M. and
Sakaki, Y. (2001) A comprehensive two-hybrid analysis to explore
the yeast protein interactome. Proc. Natl. Acad. Sci. USA 98,
4569–4574.
[36] Krogan, N.J. et al. (2006) Global landscape of protein complexes
in the yeast Saccharomyces cerevisiae. Nature 440, 637–643.
[37] Uetz, P. et al. (2000) A comprehensive analysis of protein–protein
interactions in Saccharomyces cerevisiae. Nature 403, 623–627.
[38] Li, S. et al. (2004) A map of the interactome network of the
metazoan C. elegans. Science 303, 540–543.
[39] Giot, L. et al. (2003) A protein interaction map of Drosophila
melanogaster. Science 302, 1727–1736.
[40] Matthews, L.R., Vaglio, P., Reboul, J., Ge, H., Davis, B.P.,
Garrels, J., Vincent, S. and Vidal, M. (2001) Identiﬁcation of
potential interaction networks using sequence-based searches for
conserved protein–protein interactions or interologs. Genome
Res. 11, 2120–2126.
[41] Altschul, S.F., Madden, T.L., Scha¨ﬀer, A.A., Zhang, J., Zhang,
Z., Miller, W. and Lipman, D.J. (1997) Gapped BLAST and PSI-
BLAST: a new generation of protein database search programs.
Nucleic Acids Res. 25, 3389–3402.
[42] Lehner, B. and Fraser, A.G. (2004) A ﬁrst-draft human protein-
interaction map. Genome Biol. 5, R63.
[43] Persico, M., Ceol, A., Gavrila, C., Hoﬀmann, R., Florio, A. and
Cesareni, G. (2005) HomoMINT: an inferred human network
based on orthology mapping of protein interactions discovered in
model organisms. BMC Bioinformat. 6 (Suppl. 4), S21.
[44] Valencia, A. and Pazos, F. (2002) Computational methods for the
prediction of protein interactions. Curr. Opin. Struct. Biol. 12,
368–373.
[45] Shoemaker, B.A. and Panchenko, A.R. (2007) Deciphering
protein–protein interactions. Part II. Computational methods to
predict protein and domain interaction partners. PLoS Comput.
Biol. 3, e43.
[46] Aloy, P. and Russell, R.B. (2002) Interrogating protein interac-
tion networks through structural biology. Proc. Natl. Acad. Sci.
USA 23, 23.
[47] Beltrao, P. and Serrano, L. (2007) Speciﬁcity and evolvability in
eukaryotic protein interactionnetworks. PLoSComput.Biol. 3, e25.
[48] Shoemaker, B.A. and Panchenko, A.R. (2007) Deciphering
protein-protein interactions. Part I. Experimental techniques
and databases. PLoS Comput. Biol. 3, e42.
[49] Bouwmeester, T. et al. (2004) A physical and functional map of
the human TNFalpha/ NF-kappa B signal transduction pathway.
Nat. Cell Biol. 6, 97–105.
[50] Lim, J. et al. (2006) A protein-protein interaction network for
human inherited ataxias and disorders of Purkinje cell degener-
ation. Cell 125, 801–814.
[51] Miller, J.P., Lo, R.S., Ben-Hur, A., Desmarais, C., Stagljar, I.,
Noble, W.S. and Fields, S. (2005) Large-scale identiﬁcation of
yeast integral membrane protein interactions. Proc. Natl. Acad.
Sci. USA 102, 12123–12128.
[52] Ehrhard, K.N., Jacoby, J.J., Fu, X.Y., Jahn, R. and Dohlman,
H.G. (2000) Use of G-protein fusions to monitor integral
membrane protein–protein interactions in yeast. Nat. Biotechnol.
18, 1075–1079.
[53] Guo, D., Hazbun, T.R., Xu, X.-J., Ng, S.-L., Fields, S. and Kuo,
M.-H. (2004) A tethered catalysis, two-hybrid system to identify
protein–protein interactions requiring posttranslational modiﬁca-
tions. Nat. Biotechnol. 22, 888–892.
[54] von Mering, C., Krause, R., Snel, B., Cornell, M., Oliver, S.G.,
Fields, S. and Bork, P. (2002) Comparative assessment of large-
scale data sets of protein–protein interactions. Nature 417, 399–
403.
[55] Lage, K. et al. (2007) A human phenome-interactome network of
protein complexes implicated in genetic disorders. Nat. Biotech-
nol. 25, 309–316.
[56] Rhodes, D.R. et al. (2005) Probabilistic model of the human
protein–protein interaction network. Nat. Biotechnol. 23, 951–
959.
[57] Piston, D.W. and Kremers, G.J. (2007) Fluorescent protein
FRET: the good, the bad and the ugly. Trends Biochem. Sci. 32,
407–414.
[58] Niethammer, P., Kronja, I., Kandels-Lewis, S., Rybina, S.,
Bastiaens, P. and Karsenti, E. (2007) Discrete states of a protein
R.A. Pache et al. / FEBS Letters 582 (2008) 1259–1265 1265interaction network govern interphase and mitotic microtubule
dynamics. PLoS Biol. 5, e29.
[59] Suthram, S., Sittler, T. and Ideker, T. (2005) The Plasmodium
protein network diverges from those of other eukaryotes. Nature
438, 108–112.
[60] Kelley, B.P., Sharan, R., Karp, R.M., Sittler, T., Root, D.E.,
Stockwell, B.R. and Ideker, T. (2003) Conserved pathways
within bacteria and yeast as revealed by global protein
network alignment. Proc. Natl. Acad. Sci. USA 100, 11394–
11399.
[61] Sharan, R. et al. (2005) Conserved patterns of protein interaction
in multiple species. Proc. Natl. Acad. Sci. USA 102, 1974–1979.
[62] Koyutu¨rk, M., Kim, Y., Topkara, U., Subramaniam, S., Szpan-
kowski, W. and Grama, A. (2006) Pairwise alignment of protein
interaction networks. J. Comput. Biol. 13, 182–199.
[63] Flannick, J., Novak, A., Srinivasan, B.S., McAdams, H.H. and
Batzoglou, S. (2006) Graemlin: general and robust alignment of
multiple large interaction networks. Genome Res. 16, 1169–1181.
[64] Kiemer, L. and Cesareni, G. (2007) Comparative interactomics:
comparing apples and pears? Trends Biotechnol. 25, 448–454.
[65] Sharan, R. and Ideker, T. (2006) Modeling cellular machinery
through biological network comparison. Nat. Biotechnol. 24,
427–433.
[66] Ge, X., Yamamoto, S., Tsutsumi, S., Midorikawa, Y., Ihara, S.,
Wang, S.M. and Aburatani, H. (2005) Interpreting expression
proﬁles of cancers by genome-wide survey of breadth of expres-
sion in normal tissues. Genomics 86, 127–141.
[67] Su, A.I. et al. (2004) A gene atlas of the mouse and human
protein-encoding transcriptomes. Proc. Natl. Acad. Sci. USA 101,
6062–6067.
[68] Calvano, S.E. et al. (2005) A network-based analysis of systemic
inﬂammation in humans. Nature 437, 1032–1037.[69] Levine, D.M., Haynor, D.R., Castle, J.C., Stepaniants, S.B.,
Pellegrini, M., Mao, M. and Johnson, J.M. (2006) Pathway and
gene-set activation measurement from mRNA expression data:
the tissue distribution of human pathways. Genome Biol. 7, R93.
[70] Segal, E., Friedman, N., Koller, D. and Regev, A. (2004) A
module map showing conditional activity of expression modules
in cancer. Nat. Genet. 36, 1090–1098.
[71] Subramanian, A. et al. (2005) Gene set enrichment analysis: a
knowledge-based approach for interpreting genome-wide expres-
sion proﬁles. Proc. Natl. Acad. Sci. USA 102, 15545–15550.
[72] Kell, D.B. (2006) Systems biology, metabolic modelling and
metabolomics in drug discovery and development. Drug Discov.
Today 11, 1085–1092.
[73] Laaksonen, R. et al. (2006) A systems biology strategy reveals
biological pathways and plasma biomarker candidates for poten-
tially toxic statin-induced changes in muscle. PLoS ONE 1, e97.
[74] Lamb, J. et al. (2006) The connectivity map: using gene-expres-
sion signatures to connect small molecules, genes, and disease.
Science 313, 1929–1935.
[75] Berns, K. et al. (2004) A large-scale RNAi screen in human cells
identiﬁes new components of the p53 pathway. Nature 428, 431–
437.
[76] Workman, C.T. et al. (2006) A systems approach to mapping
DNA damage response pathways. Science 312, 1054–1059.
[77] Wishart, D.S., Knox, C., Guo, A.C., Shrivastava, S., Hassanali,
M., Stothard, P., Chang, Z. and Woolsey, J. (2006) DrugBank: a
comprehensive resource for in silico drug discovery and explora-
tion. Nucleic Acids Res. 34, D668–D672.
[78] Hamosh, A., Scott, A.F., Amberger, J.S., Bocchini, C.A. and
McKusick, V.A. (2005) Online Mendelian inheritance in man
(OMIM), a knowledgebase of human genes and genetic disorders.
Nucleic Acids Res. 33, D514–D517.
